Abstract
Background/Aim
Roots of Fagara zanthoxyloides and Pseudocedrela kotchyii are used as chewing sticks and as medicinal remedies for diarrhea, cough and fever in West Africa. Extracts of the two plants also possess anti-bacterial, anti-fungal and anti-malarial activities. The aim of the present study was to determine the effects of such extracts on the growth, proliferation and induction of apoptosis in four prostate cancer cell lines.
Materials and Methods
Androgen-independent PC3 and DU-145 and androgen-dependent LNCaP and CWR-22 prostate cancer cell lines were cultured for five days with different concentrations of the extracts and examined for growth inhibition and evidence of apoptosis.
Results
Irrespective of their androgen dependence, all four cancer cell lines exhibited a dose-dependent decrease in cell proliferation and viability by the 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT) assay and in induction of apoptosis. The results also show that LNCap cells were the most sensitive to the two extracts, with highest inhibition at day 3 and exhibiting the highest rate of apoptosis.
Conclusion
These observations suggest that F. zanthoxyloides and P. kotchyii could serve as potential chemopreventive agents in the treatment of prostate cancer.
Keywords: Antiproliferative action, prostate cancer, Fagara xanthoxyloides, Pseudocedrela kotschyi.
Prostate cancer ranks as the second most commonly diagnosed cancer and the sixth in cancer mortality among men worldwide. It is also a leading cause of death among men in the United States. Over 241,000 new cases of prostate cancer will be diagnosed in 2014, along with about 28,000 deaths (1). About 903,500 new cases will also be diagnosed worldwide in 2015, with an expected number of 258,400 deaths (2). While the highest rates of prostate cancer are found in Europe and North America, it is one of the three most common types of cancer in sub-Saharan Africa (2). There are no known definitive causes of prostate cancer, but available evidence suggests that diet, genetic and hormonal factors may play a role in its pathogenesis. Hormonal involvement is suggested by published evidence that males who were castrated before puberty did not develop prostate cancer (3). Increased risk of prostate cancer among first-degree relatives of patients with the disease suggests the contribution of genetic factors (4). Other studies have also pointed to the possible role of diet as indicated by an elevated frequency of the disease in Scandinavian countries where the diet is rich in animal fat, compared to a low incidence in Japan and other Asian countries with low-fat diet (5).
Past studies have shown that some anticancer drugs inhibit prostate cell growth by inducing apoptosis and cell-cycle perturbations. Copeland et al. showed that a dichloro-naphthoquinone drug induced significant levels of apoptotic cell death in PC-3 and DU-145 prostate cell lines (6). Pourpak et al. reported that ethonafide inhibited DU-145 cell growth by inducing G2 cell-cycle arrest and inhibiting topoisomerase II activity (7). Pidgeon et al. also reported that treatment of prostate cancer cell lines PC3 and DU-145 with two inhibitors, baicalein and BHPP, resulted in a dose-dependent decrease in cell proliferation (8). Yang et al. showed that while Zanthoxyli fructus inhibited the growth of various cancer cell lines, its highest inhibitory activity was against the androgen-dependent LNCaP prostate cancer cell line (9).
Roots of Fagara zanthoxyloides and Pseudocedrela kotschyii are widely used in West Africa as chewing sticks and as medicinal remedies for a variety of ailments (10, 11). Crude and purified root extracts of the two plants inhibited stage-specific in vitro growth of the human malaria parasite Plasmodium falciparum (12, 13). Other studies have separately demonstrated that exracts of Fagara and Pseudocedrela contain several natural compounds with different biological activities (10, 14). One of these compounds is fagaronine, which was found to inhibit DNA topoisomerases I and II and act as a DNA intercalating agent (15). On the other hand, P. kotschyi has hitherto not been shown to have any anticancer activity. We, therefore, designed experiments to investigate the antiproliferative and apoptosis-inducing activities of Fagara and Pseudocedrela extracts against androgen-independent prostate cancer PC3 and DU-145 cells and androgen-dependent LNCaP and CWR-22 prostate cancer cell lines.
Materials and Methods
Plant extract preparation
The identities of the plants used in the study, P. kotschyi and F. zanthoxyloides, were confirmed by comparison with authentic specimens at the University of Lagos Herbarium. The roots of the plants were washed, air-dried, pulverized into powder form and extracted in cold sterile deionized water (20 g/l00 ml H2O) for 24 h by mechanical stirring. The aqueous extracts were centrifuged twice at 800 ×g for 15 min to remove particulate materials. The supernatants were then filter-sterilized (0.45 μm; Millipore Corp., Bedford, MA, USA) and freeze-dried in a Labconco lyophilizer (Marshall Scientific, Brentwood, NJ, USA). The dried powder extracts were used in all experiments.
Cell cultures
Stock cultures of two androgen-independent PC-3 and DU-145 and two androgen-dependent LNCaP and CWR-22 prostate cancer cell lines (Manassas, VA, USA) were propagated in complete RPMI-1640, supplemented with 10% fetal bovine serum, 2 mM L-glutamine and penicillin/streptomycin (100 ug /ml,100 units). The cultures were maintained at 37° C in a humidified atmosphere of 5% CO2 and 95% air until reaching about 80% confluency. The cells were trypsinized with trypsin-EDTA solution, stained with 0.2% trypan blue and enumerated in a hemacytometer for assessment of viability, with cell density adjusted for each experiment.
Cell proliferation
Cells (2×104 cells/well), in 200 ul of RPMI-1640 medium, were plated in triplicate in 96-well plates and allowed to grow for 24 h. The cells were then incubated with different concentrations (12, 25, 50 and 200 μg/ml) of Fagara and Pseudocedrela extracts. Control cells were similarly incubated without the extracts. For determination of cell proliferation and viability at 1, 3 and 5 days of incubation, the culture medium was aspirated and cells were treated for 3 h with 30 μl MTT colorimetric reagent (0.5 mg/ml) at 37° C. After aspiration, 100 μl of 0.04 N HCl in isopropanol was added to each well. Spectrophotometric measurements of the blue-colored product, formazan, at 570 nm with a background reading at 630 nm were used to determine cell proliferation. The amount of formazan dye is a direct measurement of the number of metabolically active cells in the culture.
Determination of apoptosis
Cells were harvested by centrifugation at 200 ×g for 5 min and washed twice with PBS to remove residual inhibitors. The cells were resuspended in 75% ethanol overnight at 4° C. The fixed cells were centrifuged, washed twice with PBS, readjusted to a volume of 200 μl with PBS and stained for 3 h with a 40-μl mixture of acridine orange (100 μg/ml) and ethidium bromide (100 μg/ml). The cells were examined under fluorescence microscopy for morphological evidence of membrane blebbing, nuclear disintegration and chromatin condensation. The proportion of apoptotic cells was calculated from multiple readings of 1,000 cells each.
Statistical analysis
All results are expressed as the cell growth as a percentage that of control cultures and each data point on graphs represents the mean of three independent experiments that were run in triplicate. The differences within and between different groups of treatments were analyzed using one-way analysis of variance (ANOVA), with p<0.05 considered statistically significant.
Results
Increasing concentrations of F. zanthoxyloides and P. kotchyii extracts were tested for their anti-proliferative and apoptosis-inducing activities on four prostate cancer cell lines over a five-day incubation period. The extract concentrations used in the experiments ranged from 12 to 200 μg/ml. The results of their effects on the proliferation of the four cell lines are presented in Figures 1–4. The Figures show that the Fagara and Pseudocedrela extracts at all concentrations had little or no effect on the growth of PC-3, DU-145 and LNCaP cells at day 1 but reduced the proliferation of the CWR-22 cells to 69% and 57% of the control only at 200 μg/ml. While the Fagara extract also did not have any appreciable effect on the PC-3 cells at day 3, the Pseudocedrela extract reduced its growth to about 61% of the control (Figure 1B). The growth of DU145 cells was reduced to 48% by Fagara extract and to 36% by the Pseudocedrela extract (Figures 2A, B). The results also show that the LNCap cells were the most sensitive to the two extracts, with their highest inhibition being found at day 3 instead of day 5 as was observed with the other three cell lines (Figures 3A, B). Irrespective of their androgen dependence, all four cell lines were reduced to their lowest levels of proliferation in a concentration-dependent manner by day 3 or 5 (Figures 1–4).
Figures 1–4.
Effects of Fagara and Pseudocedrela extracts on the proliferation of androgen-independent PC-3 and DU-145 and androgen-dependent LNCaP and CWR-22 prostate cell lines. The cells were incubated with 12, 25, 100 and 200 μg/ml for 1, 3 and 5 days and their viability was quantitatively assessed by the MTT colorimetric assay. The results are expressed as percentages of control cultures without extract incubation.
Table I shows the IC50 values for the two extracts that were derived from the proliferation graphs, using the plots for the 5-day cultures. Pseudocedrela extract had lower IC50 values of 12–20 μg/ml for PC-3, DU145 and LNCap cells, indicating that these cells were more sensitive to the extract than to the Fagara extract, which had significantly higher IC50 values of 25–44 μg/ml.
Table I.
IC50 values of Fagara and Pseudocedrela root extracts obtained from the dose response curves of 5-day cultures of the four prostate cancer cell lines.
| Prostate cell line | Fagara extract | Pseudocedrela extract |
|---|---|---|
| PC-3 | 25±2.8 μg/ml | 12±0.7μg /ml |
| DU-145 | 25±2.6 μg /ml | 12±0.8μg /ml |
| LNCaP | 39±3.5 μg /ml | 20±1.6μg /ml |
| CWR-22 | 44±3.8 μg /ml | 42±3.6μg /ml |
Table II shows the mean proportions of each cell line that were determined as viable by the MTT assay and as apoptotic at day 5 of incubation with 50 μg/ml of each of the two extracts. The LNCap cells entitled the highest proportions (42–45%) of apoptotic cells induced by the two extracts, compared to the low proportions of 24–26% for CWR-22 cells. Figure 2 shows fluorescence microscopy images of apoptosis of DU-145 cells, as indicated by membrane blebbing, chromatin condensation and nuclear disintegration after treatment with Fagara and Pseudocedrela extracts and staining with a mixture of acridine orange and ethidium bromide. Similar apoptotic images were also obtained with the three other extract-treated cell lines.
Table II.
Percent viable and apoptotic prostate cancer cell lines at 5 days of treatment with 50 μg/ml of Fagara and Pseudocedrela root extracts. Viability was determined by the MTT assay and percent apoptosis was calculated from cells stained with acridine orange and ethidium bromide.
| Prostate cell line | Percent viable cells by MTT | Percent apoptotic cells | ||
|---|---|---|---|---|
|
| ||||
| Fagara | Pseudocedrela | Fagara | Pseudocedrela | |
| PC-3 | 22±2.5% | 22±1.8% | 38±3.4% | 35±3.8% |
| DU-145 | 43±3.8% | 30±2.5% | 28±1.9% | 33±2.7% |
| LNCaP | 0±2.7% | 12±0.8% | 45±3.4% | 42±3.5% |
| CWR-22 | 40±3.4% | 42±3.2% | 26±1.7% | 24±1.5% |
Discussion
This study examined the effects of Fagara and Pseudocedrela root extracts on the in vitro growth and proliferation of four prostate tumor cell lines. The cells used included androgen-independent PC-3 and DU145 cell lines and androgen-dependent LNCaP and CWR-22 cells. We chose these four cell lines because of their reported differential responses to chemopreventive agents. The extract-treated cultures were monitored for their growth and proliferation during five days of incubation. While the extracts did not inhibit the growth and multiplication of three of the cell lines on day 1, significant dose-dependent growth inhibition of all four cell lines was evident at day 3. In particular, maximum growth inhibition of LNCaP cells was achieved by the two extracts at day 3 (Figures 3A, C). All four cell lines, irrespective of their androgen sensitivity, exhibited a dose-dependent proliferation inhibition by the two plant extracts (Figures 1–4). The results also showed that LNCap cells had the highest proportions (42–45%) of apoptotic cells after treatment with the two extracts, compared to the low proportions of 24–26% for CWR-22 cells. These observations of dose-dependent decrease of cell proliferation and induction of apoptosis are similar to the findings reported by other investigators. Kumar et al. reported a dose-dependent decrease in viability, along with an increase of DNA fragmentation of PC3 prostate cancer cell line after treatment with Azadirachta indica neem leaf extract (20). In another study, Yang et al. reported that an extract of Zanthoxyli fructus, used as seasoning in Asian countries, exhibited significant in vitro growth-inhibitory activity against leukemia, breast, lung and prostate cancer cell lines (9). They showed that the extract also inhibited androgen receptor signaling and induced apoptosis of these cell lines. In a series of reports, Singh and Agarwal showed that silibinin, derived from milk thistle, inhibited cell growth and proliferation and arrested G1G2 /M cell progression (16–18). It also induced apoptosis and suppressed tumor xenograft development of PC-3, DU145 and LNCaP prostate cancer cell lines.
All the observations from the aforementioned reports suggest that growth inhibition of the prostate cancer cell lines may be mediated by a blockage of multiple pathways, including androgen receptor (AR) signaling. Prostate cancer is a slow developing tumor and generally progresses from androgen dependence in its early stage to androgen independence in the late stage. The growth and progression of prostate cancer also involves the interaction of AR and dihydrotestosterone (DHT), which is derived from the conversion of testosterone by 5-α-reductase. The ratio of testosterone to DHT in serum is about 10:1, but the ratio is reversed in the prostate. In the Guevedoce population of the Dominican Republic, male adults are known to develop relatively small-sized prostates (19). Their testosterone levels are normal, but their DHT levels are deficient. Prostate cancer is absent in this population, suggesting that DHT may play an important role in the development of the disease. Since our study used four cell lines that were derived from prostate tumors, it is possible that the anti-growth and antiproliferative properties of our Fagara and Pseudocedrela extracts may partly be associated with the inhibition of DHT.
While we have not yet isolated and identified the active antitumor components of our two extracts; some studies have isolated biologically-active components from these two plants, including fagaronine and kotschyins A-C (10, 14, 15, 16, 21). Fagaronine has been shown to be a DNA-inter-calating agent and an inhibitor of topoisomerases I and II (16, 21). Prostate cancers produce high levels of topoisomerase II enzymes in proportion to their histological grading (22). These enzymes play a role in DNA replication and chromosome segregation through breaking and rejoining of DNA strands (23, 24). The mode of action of some anticancer agents involves the inhibition of topoisomerases. These agents include topotecan and irinotecan, which are derivatives of the natural alkaloid camptothecin (25). Others are daunorubicin and doxorubicin, which are anthracycline derivates and are topoisomerase II inhibitors (26, 27). In a previous study, we showed that a purified constituent of F. zanthoxylloides, identified as fagaronine, inhibited in vitro multiplication and stage-specific development of the malaria parasite Plasmodium falciparum (12), possibly by DNA intercalation and topoisomerase II inhibition. The inhibition of replication of the four prostate cell lines by our plant extracts may be due in part to their fagaronine content and/-or to other constituents. It is, therefore, imperative to isolate, purify and identify the anti-proliferative constituents of the two plant extracts, and determine their mode(s) of action.
Figure 5.
Representative DU145 control and cells treated with 50 μg/ml of Fagara (A) and Pseudocedrela (C) extracts on day 5. Apoptosis in treated cells is indicated by the appearance of membrane blebs and nuclear disintegration.
References
- 1.Cancer Facts & Figures. American Cancer Society Inc. Surveillance Research; 2014. www.cancer.org/downloads. [Google Scholar]
- 2.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. [DOI] [PubMed] [Google Scholar]
- 3.Wilson JD, Roehrborn C. Long-term consequences of castration in men: lesson from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab. 1999;84:4324–4331. doi: 10.1210/jcem.84.12.6206. [DOI] [PubMed] [Google Scholar]
- 4.Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91:789–794. doi: 10.1046/j.1464-410x.2003.04232.x. [DOI] [PubMed] [Google Scholar]
- 5.Chavarro JE, Stampfer MJ, Hall MN, Sesso HS, Jing M. A 22-year prospective study of fish intake in relation to prostate cancer incidence and mortality. Am J Clin Nutrit. 2008;88:1297–1303. doi: 10.3945/ajcn.2008.26419. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Copeland RL, Jr, Das JR, Bakare O, Enwerem NM, Berhe S, Hilaire K, White D, Beyene D, Kassim OO, Kanaan YM. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy- 1,4-naphthoquinone in androgen-dependent and –independent prostate cancer cell lines. Anticancer Research. 2007;27(3B):1537–46. [PubMed] [Google Scholar]
- 7.Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Expt Therap. 2007;321:1109–1117. doi: 10.1124/jpet.106.117457. [DOI] [PubMed] [Google Scholar]
- 8.Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 2002;62:2721–27. [PubMed] [Google Scholar]
- 9.Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Koeffler P, Taguchi H. Zanthoxyli fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways. Oncol Reports. 2006;15:1581–1590. [PubMed] [Google Scholar]
- 10.Hay A-E, Loset J-R, Ahua KM, Diallo D, Brun R, Hostettmann K. Limonoid orthoacetaets and antiprotozoal compounds from the roots of Pseudocedrela kotschyi. J Nat Prod. 2007;70(1):9–13. doi: 10.1021/np0680230. [DOI] [PubMed] [Google Scholar]
- 11.Imaga NO, Shaire EA, Ogbeide S, Akindele SK. In vitro biochemical investigations of the effects of Carica papaya and Fagara zanthoxyloides on antioxidant status and sickle erythrocytes. Afr J Biochem Res. 2011;5(8):226–236. [Google Scholar]
- 12.Kassim OO, Lovevsky M, Elliott B, Geall A, Amonoo H, Gordeuk VR. Effects of Effects of root extracts of Fagara zanthoxyloides on the in vitro growth and stage distribution of Plasmodium falciparum. Antimicrob Agents Chemother. 2005;49:264–8. doi: 10.1128/AAC.49.1.264-268.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kassim OO, Loyevsky M, Amonoo H, Lashley LA, Ako-Nai KA, Gordeuk VR. Inhibition of in vitro growth of Plasmodium falciparum by Pseudocedrela kotschii extract alone and in combination with Fagara zanthoxyloides. Trans Roy Soc Trop Med Hyg. 2009;103(7):698–702. doi: 10.1016/j.trstmh.2009.02.018. [DOI] [PubMed] [Google Scholar]
- 14.Quattara B, Angenot L, Guissou P, Fondu P, Dubois J, Frederich M, Jansen O, van Heugen J, Wauters J, Tits M. LC/MS/NMR analysis of isomeric divanilloylquinic acids from the root bark of Fagara zanyhoxyloides Lam. Phytochem. 2004;65:1145–1151. doi: 10.1016/j.phytochem.2004.02.025. [DOI] [PubMed] [Google Scholar]
- 15.Larsen AK, Grondard L, Couprie J, Desoize B, Comor L, Jardillier JC, Riou JF. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol. 1993;46:1403–1412. doi: 10.1016/0006-2952(93)90105-6. [DOI] [PubMed] [Google Scholar]
- 16.Singh RP, Agarwal P. Prostate cancer prevention by silibinin. Current Cancer Drug Targets. 2004;4:1–11. doi: 10.2174/1568009043481605. [DOI] [PubMed] [Google Scholar]
- 17.Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 2000;62:3063–3069. [PubMed] [Google Scholar]
- 18.Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor cell growth in athymic mice by sibilinin feeding is associated with reduced cell proliferation increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomark Prev. 2000;12:933–939. [PubMed] [Google Scholar]
- 19.Imperato-McGinley J, Zhu YS. Androgens and male physiology: the syndrome of 5α-reductase-2 deficiency. Mol Cell Endocrinol. 2002;198:51–59. doi: 10.1016/s0303-7207(02)00368-4. [DOI] [PubMed] [Google Scholar]
- 20.Kumar S, Suresh PK, Vijayababu MR, Arunkumar J. Anticancer effects of ethanolic neem leaf extract on prostate cancer cell line (PC-3) J Ethnopharmacol. 2006;105:246–250. doi: 10.1016/j.jep.2005.11.006. [DOI] [PubMed] [Google Scholar]
- 21.Fleury F, Sukhanova A, Ianoul A, Devy J, Kudelina I, Duval O, Alix AJ, Jardillier JC, Nabiev I. Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine. J Biol Chem. 2000;275:3501–3509. doi: 10.1074/jbc.275.5.3501. [DOI] [PubMed] [Google Scholar]
- 22.Hughes C, Murphy A, Martin C, Fox E, Ring M, Sheils O, Loftus B, O’Leary J. Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol. 2006;59:721–724. doi: 10.1136/jcp.2005.029975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Vogel C, Kienitz A, Muller R, Bastians H. The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. J Biol Chem. 2005;280:4025–4028. doi: 10.1074/jbc.C400545200. [DOI] [PubMed] [Google Scholar]
- 24.Walker JV, Nitiss JL. DNA topoisomerase II as a arget for cancer chemotherapy. Cancer Investig. 2002;20:570–589. doi: 10.1081/cnv-120002156. [DOI] [PubMed] [Google Scholar]
- 25.Dongsool Y, Singh RP, Agarwal C, Lee S, Hyungjoon C, Agarwal R. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005;65:1035–1044. [PubMed] [Google Scholar]
- 26.Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem. 2000;7:39–58. doi: 10.2174/0929867003375489. [DOI] [PubMed] [Google Scholar]
- 27.Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, Supino R, Zunino F. New developments in antitumor anthracyclines. Pharmacol Ther. 1997;76:117–124. doi: 10.1016/s0163-7258(97)00096-x. [DOI] [PubMed] [Google Scholar]


